Clinical Trial Detail

NCT ID NCT02411656
Title Pembrolizumab in Treating Patients With Stage IV Metastatic or Recurrent Inflammatory Breast Cancer or Triple-Negative Breast Cancer Who Have Achieved Clinical Response or Stable Disease to Prior Chemotherapy
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors M.D. Anderson Cancer Center

triple-receptor negative breast cancer

inflammatory breast carcinoma



Age Groups: senior adult

Additional content available in CKB BOOST